WO2005000332A3 - Therapeutic agent for soft tissue sarcoma - Google Patents

Therapeutic agent for soft tissue sarcoma Download PDF

Info

Publication number
WO2005000332A3
WO2005000332A3 PCT/JP2004/009371 JP2004009371W WO2005000332A3 WO 2005000332 A3 WO2005000332 A3 WO 2005000332A3 JP 2004009371 W JP2004009371 W JP 2004009371W WO 2005000332 A3 WO2005000332 A3 WO 2005000332A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
soft tissue
tissue sarcoma
sarcoma
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2004/009371
Other languages
French (fr)
Other versions
WO2005000332A2 (en
Inventor
Tatsuo Ito
Toshifumi Ozaki
Mamoru Ouchida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Priority to JP2006516853A priority Critical patent/JP4661782B2/en
Priority to MXPA06000013A priority patent/MXPA06000013A/en
Priority to AT04746840T priority patent/ATE468113T1/en
Priority to EP04746840A priority patent/EP1638541B1/en
Priority to DE602004027244T priority patent/DE602004027244D1/en
Priority to CA002529840A priority patent/CA2529840A1/en
Publication of WO2005000332A2 publication Critical patent/WO2005000332A2/en
Publication of WO2005000332A3 publication Critical patent/WO2005000332A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a therapeutic agent for soft tissue sarcoma (particularly synovial sarcoma), which contains a histone deacetylase inhibitor (particularly FK228) as an active ingredient.
PCT/JP2004/009371 2003-06-27 2004-06-25 Therapeutic agent for soft tissue sarcoma Ceased WO2005000332A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2006516853A JP4661782B2 (en) 2003-06-27 2004-06-25 Soft tissue sarcoma treatment
MXPA06000013A MXPA06000013A (en) 2003-06-27 2004-06-25 Therapeutic agent for soft tissue sarcoma.
AT04746840T ATE468113T1 (en) 2003-06-27 2004-06-25 THERAPEUTIC AGENT FOR SOFT TISSUE SARCOMA
EP04746840A EP1638541B1 (en) 2003-06-27 2004-06-25 Therapeutic agent for soft tissue sarcoma
DE602004027244T DE602004027244D1 (en) 2003-06-27 2004-06-25 THERAPEUTIC AGENT FOR A SOFT PARTICULAR ARKOM
CA002529840A CA2529840A1 (en) 2003-06-27 2004-06-25 Therapeutic agent for soft tissue sarcoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003-183643 2003-06-27
JP2003183643 2003-06-27

Publications (2)

Publication Number Publication Date
WO2005000332A2 WO2005000332A2 (en) 2005-01-06
WO2005000332A3 true WO2005000332A3 (en) 2005-03-24

Family

ID=33549590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/009371 Ceased WO2005000332A2 (en) 2003-06-27 2004-06-25 Therapeutic agent for soft tissue sarcoma

Country Status (14)

Country Link
US (2) US7056883B2 (en)
EP (2) EP1638541B1 (en)
JP (1) JP4661782B2 (en)
AT (1) ATE468113T1 (en)
CA (1) CA2529840A1 (en)
CY (1) CY1113534T1 (en)
DE (1) DE602004027244D1 (en)
DK (1) DK2238982T3 (en)
ES (2) ES2341771T3 (en)
MX (1) MXPA06000013A (en)
PL (1) PL2238982T3 (en)
PT (1) PT2238982E (en)
SI (1) SI2238982T1 (en)
WO (1) WO2005000332A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691534B2 (en) 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US8980825B2 (en) 2010-07-12 2015-03-17 Celgene Corporation Romidepsin solid forms and uses thereof
US9101579B2 (en) 2012-11-14 2015-08-11 Celgene Corporation Inhibition of drug resistant cancer cells
US9134325B2 (en) 2012-09-07 2015-09-15 Celgene Corporation Resistance biomarkers for HDAC inhibitors
US9463215B2 (en) 2013-12-27 2016-10-11 Celgene Corporation Romidepsin formulations and uses thereof
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4238728B2 (en) * 2001-08-21 2009-03-18 アステラス製薬株式会社 Medicinal uses of histone deacetylase inhibitors and methods for evaluating their antitumor effects
US8673888B2 (en) * 2002-04-05 2014-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Depsipeptide for therapy of kidney cancer
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1595952A4 (en) * 2003-02-19 2008-05-21 Astellas Pharma Inc Method of estimating antitumor effect of histone deacetylase inhibitor
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
ES2425083T3 (en) * 2003-09-25 2013-10-11 Astellas Pharma Inc. Antitumor agent comprising FK228 as a histone deacetylase and doxorubicin inhibitor as a topoisomerase II inhibitor
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20060040575A1 (en) * 2004-08-18 2006-02-23 Kelleher Karen A Reflective printing on flame resistant fabrics
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1715334A1 (en) * 2005-04-22 2006-10-25 Adamant Technologies SA Procedure utilising an electrochemical sensor and electrodes forming the sensor
NZ548087A (en) * 2005-04-29 2010-10-29 Tomizo Yamamoto Rubber or resin foam containing zirconium or germanium
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
KR100809410B1 (en) * 2005-07-06 2008-03-05 주식회사 브레인가드 Stem cell differentiation inducing composition and use thereof
EA200800321A1 (en) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. HISTONDEACETYLASE INHIBITORS
EP1920779A4 (en) * 2005-08-12 2010-03-10 Astellas Pharma Inc Technique for stabilization of yw753 reparation
AU2006283677A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
GB0518720D0 (en) * 2005-09-14 2005-10-19 Hamlet Pharma Ab Therapeutic combination
CA2627129A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer
JP2009514879A (en) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド Methods of treating cancer using SAHA, carboplatin and paclitaxel and other combination therapies
US20070197568A1 (en) * 2005-11-04 2007-08-23 Paul Bunn Methods of using SAHA and Erlotinib for treating cancer
US20070129290A1 (en) * 2005-11-18 2007-06-07 Or Yat S Metabolite derivatives of the HDAC inhibitor FK228
CN101528037A (en) * 2006-11-03 2009-09-09 默克公司 Methods of using SAHA and Bortezomib for treating multiple myeloma
CN101687010A (en) * 2006-12-29 2010-03-31 格洛斯特制药公司 Preparation of Romidepsin
JP2010516767A (en) * 2007-01-23 2010-05-20 グラスター ファーマシューティカルズ， インコーポレイテッド Combination therapy including romidepsin and I.A. bortezomib
CA2863291A1 (en) * 2012-01-12 2013-07-18 Celgene Corporation Romidepsin formulations and uses thereof
CA2887243C (en) 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
US9410943B2 (en) 2013-03-14 2016-08-09 The Board Of Trustees Of The Leland Stanford Junior University Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
EP3616754A1 (en) 2013-08-22 2020-03-04 Vanda Pharmaceuticals Inc. Cancer treatment
EP3057594A4 (en) * 2013-10-18 2017-06-07 Epizyme, Inc. Method of treating cancer
MA40367A (en) * 2014-07-03 2017-05-10 Imclone Llc Combination therapy
KR20180042356A (en) 2015-08-24 2018-04-25 에피자임, 인코포레이티드 How to treat cancer
EP3746135A4 (en) 2018-01-30 2022-03-09 Foghorn Therapeutics Inc. Methods and compounds for treating disorders
CN113874016A (en) 2019-01-29 2021-12-31 福宏治疗公司 Compound and use thereof
EP3917517A4 (en) 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. Compounds and uses thereof
US20230066136A1 (en) 2019-01-29 2023-03-02 Foghorn Therapeutics Inc. Compounds and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
US20220154282A1 (en) * 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
US12528825B2 (en) 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
EP4096651A4 (en) 2020-01-29 2024-01-24 Foghorn Therapeutics Inc. Compounds and uses thereof
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
US11767330B2 (en) 2021-07-06 2023-09-26 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60149520A (en) * 1984-01-13 1985-08-07 Ajinomoto Co Inc Antitumor agent
EP0196415A2 (en) * 1985-01-30 1986-10-08 Teruhiko Beppu Trichostatins A and C as antitumour drugs
EP0352646A2 (en) * 1988-07-26 1990-01-31 Fujisawa Pharmaceutical Co., Ltd. FR901228 Substance and preparation thereof
WO1995031977A1 (en) * 1994-05-19 1995-11-30 Sloan-Kettering Institute For Cancer Research Novel potent inducers of terminal differentiation and methods of use thereof
WO1998039965A1 (en) * 1997-03-11 1998-09-17 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
WO2002085400A1 (en) * 2001-04-24 2002-10-31 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of dna methylation and histone deacetylase
WO2002085883A1 (en) * 2001-04-23 2002-10-31 F. Hoffmann-La Roche Ag Tricyclic alkylhydroxamates, their preparation and their use as cell proliferation inhibitors
US20020192727A1 (en) * 2001-03-20 2002-12-19 Vijayasaradhi Setaluri MAP-2 as a determinant of metastatic potential
WO2003015810A1 (en) * 2001-08-21 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
EP1302476A1 (en) * 2000-07-17 2003-04-16 Fujisawa Pharmaceutical Co., Ltd. Reduced fk228 and use thereof
WO2003088954A1 (en) * 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
WO2004075859A2 (en) * 2003-02-27 2004-09-10 Institute For Cancer Prevention Treatment of canine hemangiosarcoma with a histone deacetylase inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696273A (en) * 1991-02-28 1997-12-09 Parfums Christian Dior Method for synthesizing cucurbitine
DE4137540A1 (en) * 1991-11-14 1993-05-19 Steigerwald Arzneimittelwerk USE OF PREPARATIONS OF CURCUMA PLANTS
JP3399948B2 (en) * 1992-06-26 2003-04-28 ザ トラスティーズ オブ プリンストン ユニバーシティ Method for detecting precancerous cells or cancer cells using P90 antibody or probe
IN188720B (en) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
AU2903300A (en) * 1999-03-03 2000-09-21 Ida Royalty Aps Novel pharmaceuticals, dietary supplements and cosmetic compositions, and the use of certain mixtures for preparing medicament or a dietary supplement for thetreatment or prevention of inflammation, hypersensitivity reactions or pain
CN1414971A (en) 1999-12-08 2003-04-30 埃克斯西特治疗公司 Depsipeptide and congeners thereof for use as immunosuppressants
CA2433479A1 (en) * 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60149520A (en) * 1984-01-13 1985-08-07 Ajinomoto Co Inc Antitumor agent
EP0196415A2 (en) * 1985-01-30 1986-10-08 Teruhiko Beppu Trichostatins A and C as antitumour drugs
EP0352646A2 (en) * 1988-07-26 1990-01-31 Fujisawa Pharmaceutical Co., Ltd. FR901228 Substance and preparation thereof
WO1995031977A1 (en) * 1994-05-19 1995-11-30 Sloan-Kettering Institute For Cancer Research Novel potent inducers of terminal differentiation and methods of use thereof
WO1998039965A1 (en) * 1997-03-11 1998-09-17 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
EP1302476A1 (en) * 2000-07-17 2003-04-16 Fujisawa Pharmaceutical Co., Ltd. Reduced fk228 and use thereof
US20020192727A1 (en) * 2001-03-20 2002-12-19 Vijayasaradhi Setaluri MAP-2 as a determinant of metastatic potential
WO2002085883A1 (en) * 2001-04-23 2002-10-31 F. Hoffmann-La Roche Ag Tricyclic alkylhydroxamates, their preparation and their use as cell proliferation inhibitors
WO2002085400A1 (en) * 2001-04-24 2002-10-31 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of dna methylation and histone deacetylase
WO2003015810A1 (en) * 2001-08-21 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
EP1426054A1 (en) * 2001-08-21 2004-06-09 Fujisawa Pharmaceutical Co., Ltd. Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
WO2003088954A1 (en) * 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
WO2004075859A2 (en) * 2003-02-27 2004-09-10 Institute For Cancer Prevention Treatment of canine hemangiosarcoma with a histone deacetylase inhibitor

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AILENBERG M ET AL: "Differential effects of trichostatin A on gelatinase A expression in 3T3 fibroblasts and HT-1080 fibrosarcoma cells: Implications for use of TSA in cancer therapy", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 10 JAN 2003 UNITED STATES, vol. 302, no. 2, 10 January 2003 (2003-01-10), pages 181 - 185, XP008039399, ISSN: 0006-291X *
CURTIN M ET AL: "Histone deacetylase inhibitors: The Abbott experience", CURRENT MEDICINAL CHEMISTRY 2003 NETHERLANDS, vol. 10, no. 22, November 2003 (2003-11-01), pages 2373 - 2392, XP008039441, ISSN: 0929-8673 *
DATABASE WPI Section Ch Week 198538, Derwent World Patents Index; Class B05, AN 1985-232458, XP002307872 *
JABOIN JERRY ET AL: "MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors", CANCER RESEARCH, vol. 62, no. 21, 1 November 2002 (2002-11-01), pages 6108 - 6115, XP001202151, ISSN: 0008-5472 *
KELLY W K ET AL: "Histone deacetylase inhibitors: From target to clinical trials", EXPERT OPINION ON INVESTIGATIONAL DRUGS 01 DEC 2002 UNITED KINGDOM, vol. 11, no. 12, 1 December 2002 (2002-12-01), pages 1695 - 1713, XP001202636, ISSN: 1354-3784 *
KUTKO M C ET AL: "Histone Deacetylase Inhibitors Induce Growth Suppression and Cell Death in Human Rhabdomyosarcoma in Vitro", CLINICAL CANCER RESEARCH 15 NOV 2003 UNITED STATES, vol. 9, no. 15, 15 November 2003 (2003-11-15), pages 5749 - 5755, XP008039438, ISSN: 1078-0432 *
LEE YOU MIE ET AL: "Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 300, no. 1, 3 January 2003 (2003-01-03), pages 241 - 246, XP001202149, ISSN: 0006-291X *
UEDA HIROTSUGU ET AL: "FR901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum No. 968 III. Antitumor activities on experimental tumors in mice", JOURNAL OF ANTIBIOTICS, JAPAN ANTIBIOTICS RESEARCH ASSOCIATION. TOKYO, JP, vol. 47, no. 3, 25 March 1994 (1994-03-25), pages 315 - 323, XP002960289, ISSN: 0021-8820 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US9259452B2 (en) 2006-06-08 2016-02-16 Gelgene Corporation Deacetylase inhibitor therapy
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US8691534B2 (en) 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin
US8980825B2 (en) 2010-07-12 2015-03-17 Celgene Corporation Romidepsin solid forms and uses thereof
US9518094B2 (en) 2010-07-12 2016-12-13 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US9134325B2 (en) 2012-09-07 2015-09-15 Celgene Corporation Resistance biomarkers for HDAC inhibitors
US9101579B2 (en) 2012-11-14 2015-08-11 Celgene Corporation Inhibition of drug resistant cancer cells
US9463215B2 (en) 2013-12-27 2016-10-11 Celgene Corporation Romidepsin formulations and uses thereof
US9468664B2 (en) 2013-12-27 2016-10-18 Celgene Corporation Romidepsin formulations and uses thereof
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US10849965B2 (en) 2015-05-05 2020-12-01 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11185577B2 (en) 2015-05-05 2021-11-30 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11925679B2 (en) 2015-05-05 2024-03-12 The Regents Of The University Of California H3.3 CTL peptides and uses thereof

Also Published As

Publication number Publication date
EP1638541B1 (en) 2010-05-19
SI2238982T1 (en) 2013-01-31
EP1638541A2 (en) 2006-03-29
JP2007521259A (en) 2007-08-02
PT2238982E (en) 2013-01-22
US20050107290A1 (en) 2005-05-19
US7056883B2 (en) 2006-06-06
JP4661782B2 (en) 2011-03-30
CA2529840A1 (en) 2005-01-06
DE602004027244D1 (en) 2010-07-01
EP2238982B1 (en) 2012-10-17
EP2238982B8 (en) 2013-01-16
ES2341771T3 (en) 2010-06-28
ATE468113T1 (en) 2010-06-15
EP2238982A3 (en) 2011-03-02
WO2005000332A2 (en) 2005-01-06
DK2238982T3 (en) 2013-01-28
ES2397079T3 (en) 2013-03-04
US20060223747A1 (en) 2006-10-05
MXPA06000013A (en) 2006-03-21
EP2238982A2 (en) 2010-10-13
CY1113534T1 (en) 2016-06-22
PL2238982T3 (en) 2013-03-29

Similar Documents

Publication Publication Date Title
WO2005000332A3 (en) Therapeutic agent for soft tissue sarcoma
AU2003255845A1 (en) Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
EP1650192A4 (en) Quinolone derivative or salt thereof
WO2002046129A3 (en) Inhibitors of histone deacetylase
AU2003245341A1 (en) Surgical stapling device
WO2008029404A3 (en) Pelvic anchor brace
MY136892A (en) Deacetylase inhibitors
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
EP1704856A4 (en) Hsp90 family protein inhibitor
WO2006015159A3 (en) Potassium channel inhibitors
AU2003266286A1 (en) Laser-based device for non-mechanical, three-dimensional trepanation during cornea transplants
WO2007127333A3 (en) Compositions for the treatment and prevention of eyelid swelling
AU2003248052A1 (en) N-phenyl-(2r,5s)dimethylpiperadine derivative
AU2003243285A1 (en) Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds
AU2003247390A1 (en) Histone deacetylase inhibitors based on alphachalcogenmethylcarbonyl compounds
WO2003048122A3 (en) Inhibitors of cytosolic phospholipase a2
WO2007013666A3 (en) Anti-tumor agents comprising r-spondins
WO2005058298A3 (en) Fk228 analogs and their use as hdac-inhibitors
AU2003243272A1 (en) Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
AU2003297018A1 (en) Run-time behavior preserving redundancy elimination
TW200621160A (en) Anti-termite agent
WO2005030792A3 (en) Quinoline potassium channel inhibitors
WO2005065047A3 (en) Stable oral composition containing desloratadine
TW200519126A (en) An antibacterial agent a against propionibacterium acnes
EP2366393A3 (en) Roflumilast for the treatment of pulmonary hypertension

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004746840

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2529840

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006516853

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/000013

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2004746840

Country of ref document: EP